Squarepoint
FHTX icon

Squarepoint’s Foghorn Therapeutics FHTX Stock Holding History

Squarepoint’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636K Buy
130,346
+26,603
+26% +$118K ﹤0.01% 3234
2026
Q1 		$496K Sell
103,743
-37,837
-27% -$208K ﹤0.01% 3343
2025
Q4 		$765K Buy
141,580
+104,968
+287% +$476K ﹤0.01% 2841
2025
Q3 		$179K Buy
+36,612
New +$194K ﹤0.01% 3977
2025
Q2 		– Sell
-44,040
Closed -$161K – 4658
2025
Q1 		$161K Buy
+44,040
New +$201K ﹤0.01% 4090

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Squarepoint's FHTX Position: Q2 2026 in Review

Squarepoint increased its Foghorn Therapeutics (FHTX) stake by 26% in Q2 2026, buying an estimated $118K and bringing the position to 130,346 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #3234.

Squarepoint first reported a position in FHTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $765K in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Squarepoint held 130,346 shares of Foghorn Therapeutics worth $636K as of Q2 2026.
  • Squarepoint bought 26,603 Foghorn Therapeutics shares in Q2 2026, an estimated $118K.
  • Foghorn Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3234 holding.
  • Squarepoint first reported a position in Foghorn Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Squarepoint's Foghorn Therapeutics position peaked at $765K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.